

08/28/01
J1059 U.S. PTO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Attorney's Docket: 0125-0016D3

J1050 U.S. PTO
09/939754
08/28/01

Prior Application:

Art Unit: 1631

Examiner: Y. Kim

SIR: This is a request for filing a

[] Continuation [✓] Divisional Application under 37 C.F.R. § 1.53(b) of pending prior application Serial No. 09/390,326 filed September 7, 1999 of McTigue, et al. for Modifications of the VEGF Receptor-2 Protein and Methods of Use

1. [✓] Enclosed is a complete copy of the prior application including the oath or Declaration and drawings, if any, as originally filed. I hereby verify that the attached papers are a true copy of prior application Serial No. 09/390,326 as originally filed on September 7, 1999.
2. [✓] Cancel Claims 1-16.
3. [✓] A Preliminary Amendment is enclosed.
4. [✓] The filing fee is calculated on the basis of the claims existing in the prior application as amended at 2 and 3 above.

For	Number Filed	Number Extra	Rate	Basic Fee \$710.00
Total Claims:	10	-20=	0	x\$ 18.00= \$0
Independent Claims:	1	-3=	0	x\$ 80.00= \$0
Multiple Dependent Claim(s) (if applicable)				+\$270.00=
			Total =	\$710.00
			Reduction by ½ for filing by small entity:	
			TOTAL FILING FEE	=: \$710.00

09/939754-032301

5. ☒ A check in the amount of \$710.00 to cover the filing fee is enclosed.
6. ☒ The Commissioner is hereby authorized to charge any fees which may be required including fees due under 37 C.F.R. § 1.16 and any other fees due under 37 C.F.R. § 1.17, or credit any overpayment during the pendency of this application to Deposit Account No. 50-0622.
7. ☒ Amend the specification by inserting before the first line, the sentence:

--This is a ☐ continuation ☒ division of application Serial No. 09/390,326, filed September 7, 1999 which is based upon application Serial No. 60/009,503, filed September 8, 1998--

8. ☐ New formal drawings are enclosed.
9. ☒ The prior application is assigned of record to: Agouron Pharamceuticals, Inc.
10. ☐ Priority of application Serial No. _____, filed on _____ in _____ (country) is claimed under 35 U.S.C. § 119. A certified copy ☐ is enclosed or ☐ is on file in the prior application.
11. ☐ A verified statement claiming small entity status ☐ is enclosed or ☐ is on file in the prior application.
12. ☐ The power of attorney in the prior application is to at least one of the following:
13. ☒ The power appears in the original declaration of the prior application.
14. ☐ Since the power does not appear in the original declaration, a copy of the power in the prior application is enclosed.
15. ☒ Please address all correspondence to SHANKS & HERBERT, TransPotomac Plaza, 1033 N. Fairfax St., Suite 306, Alexandria, VA 22314.
16. ☒ Recognize as associate attorney: Mark R. Shanks, Registration No. 33,781; Toni-Junell Herbert, Registration No. 34,348; Joseph Contrera, Registration No. 44,628; Christina Gadiano, Registration No. 37,628; Shelly Guest Cermak, Registration No. 39,571 of SHANKS & HERBERT; Linda Evans, Registration No. 33,873; Aubrey Haddach, Registration No. P-48,374; Ron Myers, Registration No. 43,825; Karl Neidert, Registration No. 39,313; Robert Prince, Registration No. 38,583; Joseph Reidy, Registration No. 39,390; Keith Hutchinson, Registration No. 43,687; and Jeffery Rennecker, Registration No. 40,784, of AGOURON PHARMACEUTICALS, INC.

☐ Also enclosed is _____